Related Articles
ALK inhibitors and advanced non-small cell lung cancer (Review)
Efficacy and survival outcomes of alectinib vs. crizotinib in ALK‑positive NSCLC patients with CNS metastases: A retrospective study
Response to erlotinib in a patient with lung adenocarcinoma harbouring the EML4-ALK translocation: A case report
Role of <em>STK11</em> in <em>ALK</em>‑positive non‑small cell lung cancer (Review)
Serum ProGRP and NSE levels predicting small cell lung cancer transformation in a patient with ALK rearrangement‑positive non‑small cell lung cancer: A case report